University of Arizona College of Pharmacy

Stop Our Stigma Campaign Aims to Normalize Seeking Mental Health Support for First Responders

Retrieved on: 
Thursday, July 27, 2023

PHOENIX, July 27, 2023 /PRNewswire-PRWeb/ -- EMSHelp.org, a non-profit organization committed to advancing suicide prevention among EMS providers, launched its "Stop Our Stigma" campaign on Wednesday, July 12 at the AFCA/AFDA Fire and EMS Leadership Conference and Expo 2023. Board members Rob Brewster and Dale Crogan were in attendance to request all attendees sign the pledge to "recognize and commit to reducing the stigma associated with mental health and seeking mental health help."

Key Points: 
  • EMSHelp.org and Arizona fire chiefs implore first responders to take the pledge to normalize seeking mental health help to reduce staggering suicide numbers.
  • Board members Rob Brewster and Dale Crogan were in attendance to request all attendees sign the pledge to "recognize and commit to reducing the stigma associated with mental health and seeking mental health help."
  • "We need to break that stigma and create a more compassionate society for all first responders struggling with mental health challenges."
  • All first responders are invited to join the mission to end the stigma associated with mental health and reduce the suicide rate.

New Research Shows Sleep Reset Is First & Only Digital Sleep Solution Clinically Proven to Increase Total Sleep Time by Over One Hour for Short Sleepers

Retrieved on: 
Tuesday, June 6, 2023

The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.

Key Points: 
  • The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.
  • "Remarkably, data from Sleep Reset reveals that this program has the potential to significantly extend the duration of their sleep.
  • Many popular sleep solutions like Trazadone, Benadryl and Melatonin don't even have the clinical evidence to increase total sleep time much at all.
  • Ambien and Lunesta are known to increase sleep time by around 30 minutes, but that's much less than what we've seen from Sleep Reset.

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Retrieved on: 
Thursday, March 23, 2023

The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.

Key Points: 
  • The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.
  • Rice, M.D., both of the University of Arizona College of Medicine Tucson and investigators leading the Octapharma PANS/PANDAS clinical trial.
  • "Octapharma is looking forward to sharing valuable information on PANS/PANDAS with NHIA attendees," said Octapharma USA President Flemming Nielsen.
  • For more study information, please contact Huub Kreuwel, Ph.D., Octapharma USA, Vice President of Scientific and Medical Affairs, at [email protected] or visit ClinicalTrials.gov (Identifier: NCT04508530).

Protai Adds $12 Million to Seed Round - Bringing the Total to $20 Million - to Build an Oncology Drug Discovery Pipeline

Retrieved on: 
Wednesday, March 15, 2023

TEL AVIV, Israel, March 15, 2023 /PRNewswire/ -- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced that it has added $12 million to its seed round, bringing the total amount to $20M. The round includes existing investors Grove Ventures and Pitango HealthTech and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai's oncology drug discovery pipeline, expand data acquisition as well as increase its discovery activities via pharma partnerships.

Key Points: 
  • The round includes existing investors Grove Ventures and Pitango HealthTech and was joined by Copenhagen-based Maj Invest Equity Fund .
  • The additional funding will be used to build Protai's oncology drug discovery pipeline, expand data acquisition as well as increase its discovery activities via pharma partnerships.
  • Protein-level biomarkers can predict patient populations not seen by genomic means, by directly measuring proteins, their interactions, and their functions.
  • These discoveries may be the key to significantly accelerating drug discovery and clinical development, lowering the time and costs of R&D.

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

Retrieved on: 
Tuesday, February 21, 2023

ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that several presentations were delivered at two prestigious medical conferences in February: the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting.  

Key Points: 
  • “Our trial demonstrated that 67% of extension study participants went at least 6 months without needing additional treatment.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.
  • The results from Clearside’s OASIS Phase 1/2a clinical trial were featured.
  • The data presented showed an excellent response to the therapy with 89-100% tumor control, and a favorable safety profile to date.

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Retrieved on: 
Thursday, February 2, 2023

ALPHARETTA, Ga., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in neovascular age-related macular degeneration (wet AMD) participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.

Key Points: 
  • These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data.
  • Thomas A. Ciulla, M.D., M.B.A., Chief Medical Officer and Chief Development Officer, said, “The positive data from our OASIS Extension Study reinforces our belief that CLS-AX has the potential to reduce treatment burden in patients with wet AMD while maintaining stable visual acuity.
  • In all participants in the trial, CLS-AX was well tolerated and demonstrated an excellent safety profile across all timepoints and doses.
  • The OASIS Phase 1/2a trial is complete for both the 3-month dose-escalation portion and the 3-month Extension Study.

Anivive Sponsors National Academy of Sciences Valley Fever Workshop

Retrieved on: 
Wednesday, November 16, 2022

LONG BEACH, Calif., Nov. 16, 2022 /PRNewswire/ -- Anivive Lifesciences, a technology-driven pet pharmaceutical company currently in late-stage development on the commercialization of a Canine Valley Fever Vaccine, announces they will be co-sponsoring The National Academies of Sciences, Engineering, and Medicine (NASEM) - Impact and Control of Valley Fever workshop.

Key Points: 
  • LONG BEACH, Calif., Nov. 16, 2022 /PRNewswire/ -- Anivive Lifesciences, a technology-driven pet pharmaceutical company currently in late-stage development on the commercialization of a Canine Valley Fever Vaccine, announces they will be co-sponsoring The National Academies of Sciences, Engineering, and Medicine (NASEM) - Impact and Control of Valley Fever workshop.
  • The workshop will take place on November 17th and 18th at the Arnold and Mabel Beckman Center in Irvine, CA.
  • It will feature speakers from around the world who are involved in research, development, and public health initiatives related to Valley Fever.
  • Economic valuation of coccidioidomycosis (valley fever) projections in the United States in response to climate change.

The University of Arizona College of Pharmacy and the University of Arizona Global Campus Announce a First-Time Partnership to Better Serve Alumni

Retrieved on: 
Tuesday, October 25, 2022

CHANDLER, Ariz., Oct. 25, 2022 /PRNewswire/ -- The first programmatic partnership between the University of Arizona (UArizona) and the University of Arizona Global Campus (UAGC) will launch between the Doctor of Pharmacy (PharmD) program at the UArizona R. Ken Coit College of Pharmacy and the Master of Business Administration (MBA) program at UAGC. This partnership represents an important milestone in the UAGC integration into UArizona, as it opens the door for more programmatic partnerships in the future.  

Key Points: 
  • The official launch takes place Friday, October 28, 2022, at 6 p.m. at the University of Arizona College of Pharmacy Alumni Celebration event, which is part of the UArizona Homecoming festivities.
  • "This collaboration will help our graduates broaden their skillsets and set them on a path for greater career advancement."
  • This partnership provides an easier and more affordable path for UArizona Doctor of Pharmacy alumni to pursue their MBA.
  • *The transferability of credits is subject to the University of Arizona Global Campus transfer credit policies and requires the submission of official transcripts.

Pharmacogenomics Market Report 2022: Increased Collaborations and Product Approvals to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022

The "Pharmacogenomics Market, by Technology, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacogenomics Market, by Technology, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Such approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup.
  • Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.
  • Key players operating in the global pharmacogenomics market are focusing on adoption of growth strategies such as collaborations and product approvals, which are expected to drive the market growth during the forecast period.

Study Shows COVID-19 Saliva Samples Yield Test Results as Accurate as Nasal Swabs

Retrieved on: 
Thursday, July 14, 2022

ROCKVILLE, Md., July 14, 2022 /PRNewswire-PRWeb/ -- A paper Abt Associates coauthored shows that COVID-19 specimen-collection methods other than traditional nasal swabs are accurate in detecting SARS-CoV-2 infections. SARS-CoV-2 is the virus that causes COVID-19 illness. A variety of options for testing is critical because of global supply shortages faced during a public health emergency such as a pandemic.

Key Points: 
  • A paper Abt Associates coauthored shows that COVID-19 specimen-collection methods other than traditional nasal swabs are accurate in detecting SARS-CoV-2 infections.
  • ROCKVILLE, Md., July 14, 2022 /PRNewswire-PRWeb/ -- A paper Abt Associates coauthored shows that COVID-19 specimen-collection methods other than traditional nasal swabs are accurate in detecting SARS-CoV-2 infections.
  • The normal protocol, the gold standard for testing for this type of virus, was to use traditional, soft-tipped nasal swabs.
  • The analysis showed 97 percent positive results for soft-tipped swabs, 99 percent for saliva, and 89 percent for foam-tipped swabs.